Literature DB >> 3323648

Cooperative Group of Additional Immunoglobulin Therapy in Severe Bacterial Infections: results of a multicenter randomized controlled trial in cases of diffuse fibrinopurulent peritonitis.

H J Jesdinsky1, G Tempel, H J Castrup, J Seifert.   

Abstract

A multicenter randomized controlled clinical trial, which was carried out in 10 hospitals in the Federal Republic of Germany between 1979 and 1983, studied the influence of i.v. immunoglobulin G on the mortality in patients with diffuse acute fibrinopurulent peritonitis. Altogether 288 patients were enrolled in the trial. There was no statistically significant difference in the mortality rates within the treated group (46%) vs the control group (41%). The power of the statistical test to detect a decrease of the mortality by 20% was calculated to be 0.93. This result did not change when we eliminated 50 patients not strictly obeying the entrance criteria of the analysis, or when we focused on a subgroup of patients with initial deficiency of immunoglobulin G. Factors influencing mortality were a preceding laparotomy, serum creatinine level above 2 mg/100 ml, and necessity for artificial respiration. These factors, reflecting the surgical situation and the severity of shock, essentially explain the mortality differences observed between the participating hospitals.

Entities:  

Mesh:

Substances:

Year:  1987        PMID: 3323648     DOI: 10.1007/BF01734833

Source DB:  PubMed          Journal:  Klin Wochenschr        ISSN: 0023-2173


  7 in total

Review 1.  New and old aspects of immunoglobulin application. The use of intravenous IgG as prophylaxis and for treatment of infections.

Authors:  L Hammarström; C I Smith
Journal:  Infection       Date:  1990 Sep-Oct       Impact factor: 3.553

2.  [Prognostic factors in diffuse peritonitis].

Authors:  W Barthlen; H Bartels; R Busch; J R Siewert
Journal:  Langenbecks Arch Chir       Date:  1992

Review 3.  Criteria for the appropriate drug utilisation of immunoglobulin.

Authors:  P Thürmann; S Harder
Journal:  Pharmacoeconomics       Date:  1996-05       Impact factor: 4.981

Review 4.  Intravenous immunoglobulin for treating sepsis, severe sepsis and septic shock.

Authors:  Marissa M Alejandria; Mary Ann D Lansang; Leonila F Dans; Jacinto Blas Mantaring
Journal:  Cochrane Database Syst Rev       Date:  2013-09-16

Review 5.  Polyclonal intravenous immune globulin for prevention and treatment of infections in critically ill patients.

Authors:  A Cometta; J D Baumgartner; M P Glauser
Journal:  Clin Exp Immunol       Date:  1994-07       Impact factor: 4.330

6.  Supplemental immunoglobulin (ivIgG) treatment in 163 patients with sepsis and septic shock--an observational study as a prerequisite for placebo-controlled clinical trials.

Authors:  G Pilz; S Kääb; G Neeser; I Class; U Schweigart; A Brähler; O Bujdoso; R Neumann; K Werdan
Journal:  Infection       Date:  1991 Jul-Aug       Impact factor: 3.553

7.  The effects of IgM-enriched immunoglobulin preparations in patients with severe sepsis [ISRCTN28863830].

Authors:  Simru Tugrul; Perihan Ergin Ozcan; Ozkan Akinci; Yalcin Seyhun; Atahan Cagatay; Nahit Cakar; Figen Esen
Journal:  Crit Care       Date:  2002-05-14       Impact factor: 9.097

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.